Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are...

Descripción completa

Detalles Bibliográficos
Autores principales: Crutel, Véronique, Lambert, Estelle, Penelaud, Pierre-François, Albarrán Severo, Cristina, Fuentes, Joaquin, Rosier, Antoine, Hervás, Amaia, Marret, Stéphane, Oliveira, Guiomar, Parellada, Mara, Kyaga, Simon, Gouttefangeas, Sylvie, Bertrand, Marianne, Ravel, Denis, Falissard, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254707/
https://www.ncbi.nlm.nih.gov/pubmed/33151500
http://dx.doi.org/10.1007/s10803-020-04709-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254707/
https://www.ncbi.nlm.nih.gov/pubmed/33151500
http://dx.doi.org/10.1007/s10803-020-04709-8

Ejemplares similares